Skip to main content
. 2017 Apr 27;17:294. doi: 10.1186/s12885-017-3279-4

Fig. 2.

Fig. 2

Overall survival curves for responders and non-responders in the p-DCS group and CD42b expression in the both groups. a: RECIST responders (P = 0.212; log-rank test). b: Histological responders (P = 0.016; log-rank test). c: CD42b expression in the p-DCS group (P = 0.012; log-rank test). d: CD42b expression in the control group (P = 0.033; log-rank test). DCS, docetaxel, cisplatin and S-1; RECIST, Response Evaluation Criteria in Solid Tumors